Of those with CCNE1 amplification, 1 (peritoneal carcinoma, 20 mg BD; Figure 3Q) had a best response of progressive disease, 1 (serous endometrial carcinoma; Figure 3R) SD, on study for 12 weeks, and 2 others had increased cyclin E1 expression by IHC without gene amplification: 1 with serous endometrial carcinoma (Figure 3S, with germline BRCA1 mutation) and the other with cervical adenocarcinoma (Figure 3P), both with SD for 16 and 29 weeks, respectively. This evidence concerns the gene BRCA1 and peritoneal carcinoma.